Date Filed | Type | Description |
08/18/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
08/15/2023 |
144
| Form 144 - Report of proposed sale of securities: |
08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
08/10/2023 |
8-K
| Quarterly results |
07/26/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
07/26/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
07/26/2023 |
8-K
| Quarterly results |
05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
05/11/2023 |
8-K
| Quarterly results |
04/26/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
04/26/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
04/26/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
03/31/2023 |
4
| Skvarka Jan (Director) has filed a Form 4 on Monte Rosa Therapeutics, Inc.
Txns:
| Granted 41,000 options to buy
@ $7.36, valued at
$301.8k
|
|
03/24/2023 |
3
| Skvarka Jan (Director) has filed a Form 3 on Monte Rosa Therapeutics, Inc. |
03/23/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
03/16/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
03/16/2023 |
8-K
| Investor presentation, Quarterly results |
02/14/2023 |
SC 13G/A
| Cormorant Asset Management, LP reports a 6% stake in Monte Rosa Therapeutics, Inc. |
02/14/2023 |
SC 13G/A
| PRICE T ROWE ASSOCIATES INC reports a 7.6% stake in MONTE ROSA THERAPEUTICS INC |
02/14/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
02/09/2023 |
SC 13G/A
| FMR LLC reports a 12.8% stake in MONTE ROSA THERAPEUTICS INC |
02/03/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
01/09/2023 |
8-K
| Investor presentation |
01/04/2023 |
4
| Wallace Owen B. (Chief Scientific Officer) has filed a Form 4 on Monte Rosa Therapeutics, Inc.
Txns:
| Granted 135,000 options to buy
@ $7.78, valued at
$1.1M
|
|
01/04/2023 |
4
| Warmuth Markus (President & CEO) has filed a Form 4 on Monte Rosa Therapeutics, Inc.
Txns:
| Granted 472,000 options to buy
@ $7.78, valued at
$3.7M
|
|
01/04/2023 |
4
| Nickson Philip (General Counsel) has filed a Form 4 on Monte Rosa Therapeutics, Inc.
Txns:
| Granted 123,650 options to buy
@ $7.78, valued at
$962k
|
|
01/04/2023 |
4
| Townson Sharon (Chief Technology Officer) has filed a Form 4 on Monte Rosa Therapeutics, Inc.
Txns:
| Granted 78,550 options to buy
@ $7.78, valued at
$611.1k
|
|
01/04/2023 |
4
| Jones Jullian G (Chief Business Officer) has filed a Form 4 on Monte Rosa Therapeutics, Inc.
Txns:
| Granted 77,450 options to buy
@ $7.78, valued at
$602.6k
|
|
01/04/2023 |
4
| Castle John C. (Chief Data Scientist) has filed a Form 4 on Monte Rosa Therapeutics, Inc.
Txns:
| Granted 78,500 options to buy
@ $7.78, valued at
$610.7k
|
|
01/04/2023 |
4
| Tamboli Ajim (CFO) has filed a Form 4 on Monte Rosa Therapeutics, Inc.
Txns:
| Granted 129,850 options to buy
@ $7.78, valued at
$1M
|
|
01/04/2023 |
4
| Janku Filip (Chief Medical Officer) has filed a Form 4 on Monte Rosa Therapeutics, Inc.
Txns:
| Granted 135,000 options to buy
@ $7.78, valued at
$1.1M
|
|
12/19/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
10/24/2022 |
8-K
| Quarterly results |
08/11/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
|